Cherubin, C, Sapira, J. The medical complications of drug addiction and the medical assessment of the intravenous drug user. Annals of Internal Medicine
1993; 119: 1017–1028.
Del Guidice, P. Cutaneous complication of intravenous drug abuse. British Journal of Dermatology
2004; 150: 1–10.
Dwyer, R, et al.
Prevalences and correlates of non-viral injecting-related injuries and diseases in a convenience sample of Australian injecting drug users. Drug and Alcohol Dependence
2009; 100: 9–16.
Hope, VD, et al.
A decade of spore-forming bacterial infections among European injecting drug users: pronounced regional variation. American Journal of Public Health
2012; 102: 122–125.
Darke, S, Ross, J, Kaye, S. Physical injecting sites among injecting drug users in Sydney, Australia. Drug and Alcohol Dependence
2001; 62: 77–82.
Kerr, T, et al.
High rates of primary care and emergency department use among injection drug users in Vancouver. Journal of Public Health (Oxford)
2005; 27: 62–66.
Palepu, A, et al.
Hospital utilization and costs in a cohort of injection drug users. Canadian Medical Association Journal
2001; 165: 415–420.
Morrison, A, Elliott, L, Gruer, L. Injecting-related harm and treatment seeking behaviour among injecting drug users. Addiction
1997; 92: 1349–1352.
Marks, M, et al.
Needles and the damage done: reasons for admission and financial costs associated with injecting drug use in a Central London Teaching Hospital. Journal of Infection
2013; 66: 95–102.
Takahasi, T, et al.
Type and location of injection drug use-related soft tissue infections predict hospitalization. Journal of Urban Health
2003; 80: 127–136.
Biswanger, I, et al.
High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Fransisco. Clinical Infectious Diseases
2000; 30: 579–581.
Lloyd-Smith, E, et al.
Prevalence and correlates of abscesses among a cohort of injection drug users. Harm Reduction Journal
2005; 2: 24.
Hope, VD, et al.
Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England. BMC Infectious Diseases
2008; 8: 120.
Hope, VD, et al.
The extent of injection site infection in injecting drug users: findings from a national surveillance study. Epidemiology & Infection
2010; 138: 1510–1518.
Lloyd-Smith, E, et al.
Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study. BMC Public Health
2008; 8: 405.
Salmon, AM, et al.
Injecting-related injury and disease among clients of a supervised injecting facility. Drug and Alcohol Dependence
2009; 101: 132–136.
Health Protection Agency, Health Protection Scotland, Public Health Wales, and Public Health Agency Northern Ireland. Shooting up: infections among people who inject drugs in the United Kingdom 2010. London: Health Protection Agency, November 2011.
Lamagni, TL, et al.
Severe Streptococcus pyogenes infections, United Kingdom, 2003–2004. Emerging Infectious Diseases
2008; 14: 202–209.
Irish, C, et al.
Skin and soft tissue infections and vascular disease among drug users, England [Letter]. Emerging Infectious Diseases
2007; 13: 1510–1511.
Kearns, AM, et al.
An unusual clone of MRSA causing infection in injecting drug users. Journal of Infection
2004; 49: 49–50.
Abdul-Quader, AS, et al.
Effectiveness of respondent-driven sampling for recruiting drug users in New York city: findings from a pilot study. Journal of Urban Health
2006; 83: 459–476.
Heckathorn, DD. Respondent-driven sampling: a new approach to the study of hidden populations. Social Problems
1997; 44: 174–199.
Turner, KM, et al.
The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction
2011; 106: 1978–1988.
Heckathorn, DD. Respondent-driven sampling II: deriving valid population estimates from chain-referral samples of hidden populations. Social Problems
2002; 49: 11–34.
Salganik, MJ, Heckathorn, DD. Sampling and estimation in hidden populations using respondent-driven sampling. Sociological Methodology
2004; 34: 193–239.
Pollini, RA, et al.
High prevalence of abscesses and self-treatment among injection drug users in Tijuana, Mexico. International Journal of Infectious Diseases
2010; 14 (Suppl. 3): e117–122.
Hay, G, et al.
Capture–recapture and anchored prevalence estimation of injecting drug users in England: national and regional estimates. Statistical Methods in Medical Research
2009; 18: 323–339.
Harris, RJ, et al.
Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. European Journal of Public Health
2012; 22: 187–192.
Ciccarone, D, et al.
Soft tissue infections among injection drug users – San Francisco, California, 1996–2000. Morbidity and Mortality Weekly Reports
. CDC Surveillance Summaries
2001; 50: 381–384.
French, M, et al.
Chronic illicit drug use, health services utilisation and the cost of medical care. Social Science & Medicine
2000; 50: 1703–1713.
van Beek, I, Dwyer, R, Malcom, A. Cocaine injecting: the sharp end of drug related harm!
Drug and Alcohol Review
2001; 20 (Harm Reduction Digest 14): 333–342.
Harris, H, Young, D. Care of injection drug users with soft tissue infections in San Fransisco, California. Archives of Surgery
2002; 137: 1217–1222.
Grau, L, et al.
Expanding harm reduction services through a wound and abscess clinic. American Journal of Public Health
2002; 92: 1915–1917.
Topp, L, et al.
Prevalence and predictors of injecting-related injury and disease among clients of Australia's needle and syringe programs. Australian and New Zealand Journal of Public Health
2008; 32: 34–37.
Murphy, E, et al.
Risk factors for skin and soft-tissue abscesses among Injection drug users: a case-control study. Clinical Infectious Diseases
2001; 33: 35–40.
Spijkerman, I, van Ameijden, EJ, Mientjes, G. Human immunodeficiency virus and other risk factors for skin abscesses and endocarditis among injection drug users. Journal of Clinical Epidemiology
1996; 49: 1149–1154.
Vlahov, D, et al.
Bacterial infections and skin cleaning prior to infection among intreavenous drug users. Public Health Reports
1992; 107: 595–598.
NICE. Needle and syringe programmes: providing people who inject drugs with injecting equipment. National Institute for Health and Clinical Excellence, Public Health Guidance, PH18, February 2009 (http://guidance.nice.org.uk/PH18).
Harm Reduction Works. National Treatment Agency for Substance Use and Exchange Supplies (www.harmreductionworks.org.uk/). Accessed 15 August 2013.